First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors.
Ravit GevaMark VoskoboynikKonstantin DobrenkovKapil MayawalaJennifer GwoRichard WnekElliot ChartashGeorgina V LongPublished in: Cancer (2020)
MK-1248 was generally well tolerated at doses up to 170 (monotherapy) and 60 mg (combination), with no DLTs or treatment-related deaths. Combination therapy provided limited antitumor responses.
Keyphrases